Abstract
We aimed to characterize real-world use of antivirals and antibiotics in patients with COVID-19 and their associations with mortality. We conducted a real-world retrospective cohort study in 688 primary-to-tertiary medical units in Mexico City; 395,343 patients were evaluated for suspected COVID-19 between February 24 and September 14, 2020. All patients with a positive RT-PCR for SARS-CoV-2 (n=137,012) were included; those receiving unspecified antivirals (n=137), excluded, and groups of antivirals with <30 patients (n=20), eliminated. Survival and mortality risk analyses were done for patients receiving antivirals, antibiotics, both, or none (exposition groups). 136,855 patients were analyzed; mean age 44.2 (SD:16.8) years; 51.3% were men. 16.6% received an antiviral (3%), antibiotic (10%), or both (3.6%). More symptomatic patients received antivirals and antibiotics more often. Antivirals studied were Oseltamivir (n=8414), Amantadine (n=319), Lopinavir-Ritonavir (n=100), Rimantadine (n=61), Zanamivir (n=39), and Acyclovir (n=36). Survival with antivirals (73.7%, P<.001) and antibiotics (85.8%, P<.001) was lower than no antiviral/antibiotic (93.6%) in the general population. Increased risk of death was observed with antivirals in ambulatory (HR=4.7, 95%CI:3.94-5.62) and non-critical (HR=2.03, 95%CI:1.86-2.21) patients; no benefit in hospitalized and critical patients. Oseltamivir was associated with increased mortality in the general population (HR=1.72, 95%CI:1.61-1.84), ambulatory (HR=4.79, 95%CI:4.01-5.75), non-critical (HR=2.05, 95%CI:1.88-2.23), and pregnancy (HR=8.35, 95%CI:1.77-39.30). Antibiotics were a protective factor in hospitalized (HR=0.81, 95%CI:0.77-0.86) and critical patients (HR=0.67, 95%CI:0.63-0.72), but a risk factor in the general population (HR=1.13, 95%CI:1.08-1.19) and children and adolescents (HR=4.22, 95%CI:2.01-8.86). In conclusion, oseltamivir was associated with increased mortality or no benefit in all groups. Common antivirals for COVID-19 should be avoided. Antibiotics may increase survival in hospitalized and critical patients. Vaccination history and rapid differentiation of etiologic agent will be key to promptly initiate or avoid antivirals during the COVID-19-influenza season.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a retrospective study using an open-source dataset of patients receiving medical care for suspected COVID-19 in Mexico City. The Secretariat of Health of Mexico approved the collection and publication of data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data Availability
Data are available upon reasonable request
